ClinicalTrials.gg
RecruitingNCT05857514Updated Jun 28, 2023

Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis

An interventional study of Rectal Indomethacin and Prophylactic Pancreatic duct stenting in Post-ERCP Acute Pancreatitis, sponsored by Moti Lal Nehru Medical College. Recruiting at 2 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Moti Lal Nehru Medical College · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing indomethacin in Pancreatitis — 6 open to participants now, 6 under way, 1 of them phase 3. Indomethacin · Pancreatitis.

Planned enrollment
12th of 20
384 · median 492
Started
2023
the only one that year
No phase
6 of 20
2 open now
Registered
15th of 20
by date
Lead sponsor
1 of 20
Moti Lal Nehru Medical College

Among the 20 studies testing indomethacin in Pancreatitis, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 6 with no phase, and was the 15th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

6 of the 20 studies testing indomethacin in Pancreatitis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About indomethacin

Indomethacin: first FDA approval 1965 (INDOCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing indomethacin in Pancreatitis, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis. The main question it aims to answer is: whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis Participants will be patients who give consent to the study and who are required to undergo ERCP as part of their standard care.

If there is a comparison group: Researchers will compare [rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis.] to see if [whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis].

03

Conditions studied

  • Post-ERCP Acute Pancreatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Suspected sphincter of Oddi dysfunction
  2. History of post ERCP Pancreatitis
  3. Pancreatic instrumentation or sphincterotomy.
  4. Precut sphincteroyomy
  5. Difficult cannulation defined by more than 5 cannulation attempts
  6. The use of double wire technique in bile duct access
  7. At least 2 of the followings including

    1. Female age \< 50 year
    2. 3 pancreatogram
    3. Acinarization (Contrast injection to tail of pancreas
    4. Normal serum
    5. Guidewire to the tail of pancreas or secondary branches

Exclusion criteria

Exclusion Criteria:

  1. Patient planned for pancreatic stenting
  2. Without
  3. Age \< 18 years
  4. Pregnant women
  5. Lactating women
  6. Patient with altered anatomy
  7. to the use of NSAIDS
  8. Renal failure
  9. Ongoing or recent hospitalisation for acute pancreatitis
  10. Allergy to aspirin or NSAIDs
  11. known chronic calcific pancreatitis -
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
384 participants (estimated)

Study arms

  • Active comparator
    Rectal indomethacin

    Drug: Rectal Indomethacin

  • Active comparator
    Pancreatic duct stent and rectal indomethacin

    Procedure: Prophylactic Pancreatic duct stenting

Interventions

  • DrugIndomethacinStudies of IndomethacinIndomethacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis

  • ProcedureProphylactic Pancreatic duct stenting

    Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis

    Also known as: Rectal indomethacin 100 mg

06

What researchers measure

Primary outcomes

  1. To compare rectal indomethacin alone versus combined pancreatic duct stent and rectal indomethacin in prevention of post ERCP pancreatitis

    For comparison between these two arms the investigators will measure serum amylase in U/L value after 6 hour and 24 hour of the ERCP procedure. The investigators will also assess for pain abdomen and vomiting suggestive of acute pancreatitis.

    Time frame: 24 hour

07

Study locations

1 of 2 sites recruiting
  • Department of Gastroenterology and Hepatology, MLN Medical college and SRN Hospital
    Allahābād, Uttar Pradesh 211001, India
    Not yet recruiting
  • Department of Gastroenterology and Hepatology
    Allahābād, Uttar Pradesh 211001, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2024, 11 months after the start.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 11 months is below that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2023
First posted
May 12, 2023
StartActual
May 10, 2023
Primary completionEst.
May 1, 2024
CompletionEst.
May 1, 2024
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05857514
Lead sponsor
Moti Lal Nehru Medical College
Responsible party
Mukti Prakash Meher (Principal investigator, Moti Lal Nehru Medical College) — Principal investigator
First posted
May 12, 2023
Start date
May 10, 2023
Primary completion
May 1, 2024 (estimated)
Completion
May 1, 2024 (estimated)
Last update
Jun 28, 2023

Study contacts

Mukti Pr Meher, MBBS, MD
Contact
drmuktiprakash@gmail.com
9556694521 ext. 9178719869
Sugata N Biswas, MBBS, MD DM
Contact
biswassugatan@gmail.com
9007073201
Mukti Pr Meher, MBBS, MD
principal investigator · Investigator

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indomethacin

Start the discussion